Schizophrenia: Normal Sequence in the Dopamine D₂ Receptor Region that Couples to G-Proteins. DNA Polymorphisms in D₂

Philip Seeman, M.D., Ph.D., Koichi Ohara, M.D., Ph.D., Carla Ulpian, M.Sc.,
Mary V. Seeman, M.D., Kurt Jellinger, M.D., Hubert H.M. Van Tol, Ph.D.,
and Hyman B. Niznik, Ph.D.

Because dopamine (DA) D₂ receptors are a target in neuroleptic therapy and have been found to be elevated in schizophrenia, the human DA D₂ receptor gene was examined for possible abnormalities in schizophrenia. Moreover, since D₂ receptors in psychosis have a reduced coupling to D₁ receptors, the cytoplasmic third loop of D₂ was chosen for deoxyribonucleic acid (DNA) sequencing, since this region is essential for coupling to G-proteins. This region also contains exon 5, which is expressed in

the long form of D₂, but not in the short form of D₂. In eight schizophrenia cases, this region had normal exon sequences (exons 4, 5 and 6), and normal sequences at its intron-exon junctions. However, exon 6 contained three DNA polymorphic base changes, and introns 4 and 5 revealed three missing bases and two polymorphic base changes, none of which would be expected to alter the D₂ receptor protein in schizophrenia.

[*Neuropsychopharmacology* 8:137-142, 1993]

KEY WORDS: Schizophrenia; Dopamine D₂ receptor; Deoxyribonucleic acid sequence; Polymorphism; Polymerase chain reaction

The human dopamine (DA) D₂ receptor is a candidate for examination of its possible genetic abnormalities in schizophrenia because the D₂ receptor is the common target of antipsychotic drug action (Seeman et al. 1976), with the single exception of clozapine, which targets to the DA D₄ receptor (Van Tol et al. 1991).

An additional reason for examining the D₂ receptor sequence is that D₂ receptors are consistently ele-

vated in postmortem schizophrenia brain tissues (Seeman et al. 1987; reviewed by Seeman and Niznik 1990), suggesting that these receptors may have an abnormal molecular structure associated with their elevated density. The density of D₂ receptors is also elevated in postmortem schizophrenia tissues from never-medicated patients (Joyce et al. 1989). There is a bimodal pattern to these elevated D₂ densities (Seeman et al. 1984, 1987) insofar as half the postmortem tissues reveal D₂ densities beyond the normal range, and the other half reveal densities in the normal range.

Using [¹¹C]methylspiperone, positron-emission tomography (PET) also reveals elevated densities of D₂-like receptors in never-medicated living schizophrenic patients (Wong et al. 1986). Using [¹¹C]raclopride, Farde et al. (1990) found that D₂ receptors in the schizophrenic left putamen were significantly elevated by 2.8 pmol/mL compared to the schizophrenic right putamen. However, although the left schizophrenic putamen was also elevated by 3.2 pmol/mL when compared to control subjects, this elevation did not reach statistical significance. Using [¹¹C]raclopride to mea-

From the Departments of Pharmacology (PS, KO, CU, HHMT), and Psychiatry, Clarke Institute of Psychiatry, Molecular Neurobiology Section (HBN, HHMT), University of Toronto; the Department of Psychiatry, Mount Sinai Hospital (MVS), Toronto, Canada; and the Ludwig Boltzmann Institute for Neurobiology, Lainz Hospital, Vienna, Austria (KJ).

Address reprint requests to: Philip Seeman, M.D., Ph.D., Department of Pharmacology, Medical Sciences Building, University of Toronto, Toronto, Ontario, Canada M5S 1A8.

Received November 12, 1991; revised March 26, 1992; accepted March 31, 1992.

sure D₂ receptors in never-medicated schizophrenic patients, Hietala et al. (1991) found that four of eleven patients revealed D₂ receptor densities elevated beyond the control group, although the overall densities between the two groups were similar. (The absolute densities of D₂ receptors reported by Hietala et al. were abnormally high, presumably a consequence of using the cerebellum as baseline, see below).

To help resolve these different findings obtained by PET, we examined the role of endogenous DA on the PET ligands. Both our in vitro and in vivo data clearly show that endogenous DA markedly lowers the apparent D₂ density when using [³H]raclopride, but not when measured using [³H]spiperone or [³H]methylspiperone (Seeman et al. 1989a, 1990). Thus, radioactive raclopride underestimates D₂ in the presence of DA.

Furthermore, when the cerebellum is used as baseline (Farde et al. 1990), the apparent value for the total D₂ density is artificially raised, resulting in a further underestimate of the percent elevation in D₂ density (Seeman et al. 1990). These findings have been supported by Ross and Jackson (1989).

Although linkage between the D₂ receptor gene region and schizophrenia has been excluded in two schizophrenia pedigrees (Moises et al. 1991), schizophrenia is sufficiently heterogeneous to warrant a search for possible D₂ receptor abnormalities in schizophrenic individuals from different pedigrees.

The present study, therefore, examined genomic deoxyribonucleic acid (DNA) from eight schizophrenic individuals. We focused on the midregion of the D₂ receptor (encoded by exons 4, 5, and 6), because this region is thought to associate with G-proteins (O'Dowd et al. 1988, 1989; Ohara et al. 1988), an association that appears disrupted or reduced in schizophrenia (Seeman et al. 1989). This region also contains an exon (exon 5), encoding 29 amino acids in the third cytoplasmic loop connecting the fifth and sixth transmembrane helices. This exon is expressed in the long form of D₂, but not in the short form of D₂.

We found the exon 4 to 6 region of the D₂ receptor to have a normal amino acid sequence in schizophrenia, but there were several polymorphisms.

MATERIALS AND METHODS

Tissues

Three schizophrenia striata were from the Lainz Hospital brain bank (Vienna), two schizophrenia striata and two control striata were from the Canadian Brain Tissue Bank (Toronto), and two blood samples were from consenting schizophrenic patients in the Toronto Schizophrenia Registry. The diagnostic criteria for schizophrenia were International Classification of Diseases, version 9 for tissues from Vienna, and DSM-III-R

(American Psychiatric Association 1987) for cases from Toronto. Two tissue samples from two schizophrenics (T751 and T708) had previously been found to have a reduced link between D₁ and D₂ receptors (see companion paper by Ohara et al. 1993; Seeman et al. 1989).

DNA Amplification By the Polymerase Chain Reaction

Genomic DNA was extracted from each tissue sample (Ohara et al. 1992). As illustrated in Figure 1, the following regions of the D₂ receptor gene were selectively amplified in vitro by the polymerase chain reaction (PCR) using *Taq* polymerase with the oligonucleotide primers indicated:

1. Between the end of intron 3 and the start of intron 4 (using Primers 753 and 752), thus including exon 4, which contains the fifth transmembrane region of the D₂ receptor.
2. Between the end of intron 4 and the beginning of intron 5 (using Primers 61 and 60). This region includes exon 5, which encodes a 29-amino acid peptide, included in the long form of D₂, but excluded from the short form of D₂ (Grandy et al. 1989; Dal Toso et al. 1989).
3. Between the end of intron 5 and the beginning of intron 6 (using Primers 751 and 750), thus including exon 6, which contains a portion of the sixth transmembrane region of the D₂ receptor.

Attached to each of the six primers were an additional nine nucleotide bases (**tacggatcc**), encoding the *Bam*HI site (see Table 1). The PCR was done in tubes containing 200 ng genomic DNA, 1 µg of each primer, 200 µmol each of adenosine 5'-triphosphate, cytidine 5'-triphosphate, guanosine 5'-triphosphate, and thymidine 5'-triphosphate, and 2.5 U of *Taq* polymerase in a final total volume of 100 µl GeneAmp buffer (Perkin-Elmer Cetus Instruments, Norwalk, CT). Each PCR cycle consisted of 1.5 minutes at 95°C to denature the genomic DNA, 2 minutes at 60°C to permit the primers to anneal, and 3 minutes at 72°C for primer extension. A total of 30 cycles were done in a DNA Thermal Cycler (Perkin-Elmer Cetus Instruments). A final period of 7 minutes at 72°C was allowed for maximum DNA extension. An aliquot (60 µL) of PCR-amplified DNA was subcloned into SP73 (Promega) and subsequently sequenced by the standard dideoxy chain termination method (see Ohara et al. 1992 for references).

RESULTS

The PCR-amplified DNA from the control and schizophrenia tissues, when run on agarose gel, revealed identical sizes for each fragment amplified (data not shown). The Southern blots, probed with exon 5, did

Figure 1. Map of the human DA D₂ receptor, amalgamated from Grandy et al. (1989) and Dal Toso et al. (1989). Lower case letters indicate noncoding bases; capitals indicate coding bases. Only the coding bases are numbered, using the scheme of Grandy et al. (1989). Primers 753, 752, 61, 60, 751, and 750, used to sequence the D₂ receptor in schizophrenia, are boxed. Missing or replaced bases are indicated, but see Table 1 for which individuals revealed changes. Boxed amino acids indicate the seven hydrophobic transmembrane regions of the D₂ receptor.

Table 1. Primer Sequence. The First Nine Nucleotide Bases (in Lower Case) Encode a *Bam*HI Site. Primers 752, 60, and 750 are Complementary to the DNA Coding Sequence of the Region Indicated in Figure 2

Primer Name	Sequence (5' to 3')	Region
753	tacggatccGGAAGGACATGAATGGGCTCTTGTGGAATTAT	Intron 3
752	tacggatccCCTTTAGCCTAGACCTAACCCTTGCTGAG	Intron 4
61	tacggatccCACGTGAGAAGGGACGTGAGTGTGCCTAGC	Intron 4
60	tacggatccCACATCCATGCCTTGACAGAACCGAGGTGTC	Intron 5
751	tacggatccTGAAAGGGAGGGGCCAGTGAGATGGGTGGCTGA	Intron 5
750	tacggatccAATGCTAGCCCCATGATCCTGCAGCCATGG	Intron 6

not reveal any differences between the control and schizophrenic tissues.

The PCR-amplified DNA was sequenced and compared to the previously published sequence of D₂ (Grandy et al. 1989; Dal Toso et al. 1989). The observed changes are shown in Fig. 1 and Table 2. None of these changes would result in a different amino acid sequence.

DISCUSSION

The polymorphic changes in the nucleotide sequences on both sides of exon 5 in both normal and schizophrenia individuals are unlikely to influence the splicing of exon 5. It should be noted the *Taq* polymerase has a base misincorporation rate of about 0.1%. It is possible, therefore, that an apparent DNA polymorphism may arise as a PCR-generated artifact. Other types of

PCR procedures can be done to rule out such artifacts. It should also be noted that the numbering here of exons 4, 5, and 6 follows that of Grandy et al. (1989), but corresponds to exons 5, 6, and 7, respectively, of Mack et al. (1991, see references therein).

Exons 4, 5, and 6 of the D₂ receptor encode the so-called third cytoplasmic loop, a region that couples to G-proteins. Since these exon sequences were normal in the tissues examined here, it suggests that possible abnormalities in D₂ coupling to G-proteins in schizophrenia (Seeman et al. 1989) would not likely be based on the structure of this region of the D₂ receptor. However, additional research needs to be done to examine all the D₂ exons and all the intron-exon junctions.

The number of different samples tested here was small. Hence, the results do not preclude an abnormal amino acid sequence in the D₂ DA receptor of other, different patients. It may be calculated that studying eight subjects is not sufficient to rule out a receptor mu-

Table 2. Changes in the Nucleotide Sequence of the Human DA D₂ Receptor in Schizophrenia and Control Individuals, Compared to the Published Normal Sequence

Base:	Intron 4			Intron 5			Exon 6		
	-208	-175	Exon 5	-46	-24	-9			
	Before Exon 5	Before Exon 5		Before Exon 6	Before Exon 6	Before Exon 6	939	957	1101
Grandy et al.	A	T	GTT	G	G	T	CAT	CCC	AAG
Amino acid:			Val				His	Pro	Lys
SZ V185-80	absent	C	T			C	C	C	G
SZ V232-81			T		absent	C	C	C	G
SZ V375-83	absent	C	T	absent	absent	C	C	T	G
									A
SZ V433-88	absent	C	T		absent	C	C	C	G
SZ T 708			T						
SZ T 751			T						
SZ TB 1	absent	C	T		absent	C	C	T	G
SZ TB 2	absent	C	C						
Control T545					absent	C	C	C	G
Control T590	absent	C	T						
Control T813		C	T	absent	absent	C	C	C	G
Dal Toso et al.							C	C	G
Selbie et al.							C	T	G
Stormann et al.							T	C	G
Sarker et al.					absent	C	C/T		

lation in possibly one-third of schizophrenic patients. A more rapid method for screening possible mutations in a larger series of tissues is to use PCR and denaturing gradient gel electrophoresis (Sung et al. 1991; Catalano et al. 1991).

The absence of changes in the D₂ receptor protein in these schizophrenia cases does not rule out other types of possible D₂ receptor abnormalities in schizophrenia (abnormal D₂ receptor phosphorylation and glycosylation, for example).

ACKNOWLEDGMENTS

Koichi Ohara is on leave from the Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Japan. We thank Dr. T. P. Morley and Maria Pataki of the Canadian Brain Tissue Bank (supported by the Medical Research Council of Canada and the Ontario Mental Health Foundation, located at the Banting Institute and the Clarke Institute of Psychiatry, University of Toronto, Toronto) for providing three postmortem brain tissues. We thank Dr. Katherine Siminovitch (Research Institute, Mount Sinai Hospital, Toronto) for preparing the DNA from the blood samples. This investigation was supported, in part, by the Medical Research Council of Canada (Grants MA 2951, PG 11121, and Studentship to Roger K. Sunahara); by the Ontario Mental Health Foundation (grant 938 and a Senior Research Fellowship to Philip Seeman); by the Ontario Ministry of Health (Career Scientist Awards to Hyman B. Niznik and Hubert H. M. Van Tol); by The Canadian Psychiatric Research Foundation (to Drs. Mary V. Seeman and K. Siminovitch); by the National Alliance for Research in Schizophrenia and Depression (Chicago and New York); by the Constance E. and Stephen Lieber Award in Schizophrenia Research; and by the Joey and Toby Tannenbaum Award of the Canadian Psychiatric Research Foundation.

REFERENCES

- American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, ed 3, Revised. Washington, DC, American Psychiatric Press
- Catalano M, Nobile M, Novelli E, Marino C, Smeraldi E (1991): Use of PCR and DGGE to detect possible genetic variations in dopamine D₂ receptor gene: A preliminary report. In Racagni G, Brunello N, Fukuda T (eds); *Biological Psychiatry*, Vol 2, Amsterdam, Excerpta Medica, pp 469–471
- Dal Toso R, Sommer B, Ewert M, Herb A, Pritchett DB, Bach A, Shivers BD, Seeburg PH (1989): The dopamine D₂ receptor: two molecular forms generated by alternative splicing. *EMBO J* 8:4025–4034
- Farde L, Wiesel, F-A, Stone-Elender S, Halldin C, Nordström A-L, Hall H, Sedvall G (1990): D₂ dopamine receptors in neuroleptic-naïve schizophrenic patients: A positron emission tomography study with [¹¹C]raclopride. *Arch Gen Psychiatry* 47:213–219
- Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L, Fischer JB, Burke-Howie KJ, Bunzow JR, Server AC, Civelli O (1989): Cloning of the cDNA and gene for a human D₂ dopamine receptor. *Proc Natl Acad Sci USA* 86:9762–9766
- Hietala J, Syvälahti E, Vuorio K, Nägren K, Lehtikainen P, Ruotsalainen U, Rääköläinen V, Lehtinen V, Wegelius U (1991): Striatal dopamine D₂ receptor density in neuroleptic-naïve schizophrenics studied with positron emission tomography. In Racagni G, Brunello N, Fukuda T (eds), *Biological Psychiatry*, Vol 2. Amsterdam, Excerpta Medica, pp 386–387
- Joyce JN, Lexow N, Bird E, Winokur A (1988): Organization of dopamine D₁ and D₂ receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia. *Synapse* 2:546–557
- Mack KJ, Todd RD, O'Malley KL (1991): The mouse dopamine D₂ receptor gene: Sequence homology with the rat and human genes and expression of alternative transcripts. *J Neurochem* 57:795–801
- Moises HW, Gelernter J, Giuffra LA, Zarcone V, Wetterberg L, Civelli O, Kidd KK, Cavilli-Sforza LL, Grandy DK, Kennedy JL, Vinogradov S, Mauer J, Litt M, Sjögren B (1991): No linkage between D₂ dopamine receptor gene region and schizophrenia. *Arch Gen Psychiatry* 48:643–647
- O'Dowd BF, Lefkowitz RJ, Caron MG (1989): Structure of the adrenergic and related receptors. *Annu Rev Neurosci* 12:67–83
- O'Dowd BF, Nguyen T, Tirpak A, Jarvie KR, Israel Y, Seeman P, Niznik HB (1990): Cloning of two additional catecholamine receptors from a rat brain. *FEBS Lett* 262:8–12
- Ohara K, Haga K, Berstein G, Haga T, Ichiyama A, Ohara K (1988): The interaction between dopamine D₂ receptors and GTP-binding proteins. *Mol Pharmacol* 33:290–296
- Ohara K, Ulpian C, Seeman P, Sunahara R, Niznik HB (1993): Schizophrenia: Dopamine D₁ receptor sequence is normal, but has DNA polymorphisms. *Neuropsychopharmacology* 8:131–135
- Ross SB, Jackson DM (1989): Kinetic properties of the accumulation of [³H]raclopride in the mouse brain in vivo. *Nucl. Pharm. Arch Pharmacol* 340:6–12
- Sarkar G, Kapelner S, Grandy DK, Marchionni M, Civelli O, Sobell J, Heston L, Sommer SS (1991): Direct sequencing of the dopamine D₂ receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural change in the receptor. *Genomics* 11:8–14
- Seeman P, Niznik HB (1990): Dopamine receptors and transporters in Parkinson's disease and schizophrenia. *FASEB J* 4:2737–2744
- Seeman P, Lee T, Chau-Wong M, Wong K, (1976): Antipsychotic drug doses and neuroleptic/dopamine receptors. *Nature* 261:717–719
- Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, Gabriel E, Reynolds GP, Tourtellotte WW (1984): Bimodal distribution of dopamine receptor densities in the brains of schizophrenics. *Science* 225:728–731
- Seeman P, Bzowej NH, Guan H-C, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW (1987): Human brain D₁ and D₂ dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. *Neuropsychopharmacology* 1:5–15
- Seeman P, Guan H-C, Niznik HB (1989a): Endogenous dopamine lowers the dopamine D₂ receptor density as mea-

- sured by [^3H]raclopride: Implications for positron emission tomography of the human brain. *Synapse* 3:96–97
- Seeman P, Niznik HB, Guan H-C, Booth G, Ulpian C (1989b): Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. *Proc Natl Acad Sci USA* 86:10156–10160
- Seeman P, Niznik HB, Guan H-C (1990): Elevation of dopamine D₂ receptors in schizophrenia is underestimated by radioactive raclopride. *Arch Gen Psychiatry* 47:1170–1172
- Selbie LA, Hayes G, Shine J (1989): The major dopamine D2 receptor: Molecular analysis of the human D_{2A} subtype. *DNA* 8:683–689
- Stormann TM, Gdula DC, Weiner DM, Brann MR (1990): Molecular cloning and expression of a dopamine D2 receptor from human retina. *Mol Pharmacol* 37:1–6
- Sung C-H, Davenport CM, Hennessey JC, Maumenee IH, Jacobson SG, Heckenlively JR, Nowakowski R, Fishman G, Gouras P, Nathans J (1991): Rhodopsin mutations in autosomal retinitis pigmentosa. *Proc Natl Acad Sci USA* 88:6481–6485
- Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991): Cloning of a human dopamine D4 receptor gene with high affinity for the antipsychotic clozapine. *Nature* 350:614–619
- Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JKT, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MH, Gjedde A (1986): Positron emission tomography reveals elevated D2 dopamine receptors in drug-naïve schizophrenics. *Science* 234:1558–1563
- World Health Organization (1979): Manual of the International Classification of Diseases, Injuries, and Causes of Death. 9th Revision, Clinical Modification. Geneva, World Health Organization